Kidney Cancer Clinical Trials & Research

Clinical trials are research studies that test new ways to treat your cancer. They test new treatments, procedures, or devices to see how well they work and whether they might be even more effective than the many standard strategies we already have established to treat kidney cancers. Clinical trials are an important part of helping to steadily improve our understanding of how to best prevent, treat, and cure cancer.

Trials can research a new diagnostic test for studying tumor tissue or a new medication or combination of medications. They can study a new way to do surgery or radiation therapy or a new type of scan.

Almost every cancer treatment given to patients was first tested during a clinical trial. That includes all of the medications now used to treat metastatic kidney cancer.

Doctors perform a clinical trial when they’re hopeful the new strategy is more effective than current treatment. Clinical trials may study:

  • A new medication that has not been tested in patients.
  • Applying an existing medication in a new way.
  • Combining 2 or more existing medications that have not been used together.

MSK’s kidney cancer team is leading clinical trials to investigate new therapies for people with kidney cancer. All our trials take place in a controlled, safe setting with teams of doctors, nurses, data coordinators, and imaging experts to make sure patients gain the best possible benefit as they participate in research studies. Researchers follow strict rules to make sure that clinical trials are as safe as possible.

Our group has led many clinical trials that resulted in medications being approved for use around the world. MSK carries out many clinical trials and is always adding new research studies. At MSK, we give our patients early access to promising new treatment options through these mechanisms. This research adds considerably to the ever-growing portfolio of options we can offer to our patients with kidney cancer.

We’re here for you. 

Get in touch.

Make an appointment with an MSK cancer expert. Call us, check out our locations, or get care from the comfort of your home with an MSK telemedicine visit. 

and/or
24 Clinical Trials found
A Phase 1 Study of Casdatifan Alone and With Zimberelimab in People With Clear Cell Kidney Cancer
Researchers are studying how casdatifan, alone or with zimberelimab, works in people with kidney cancer. The people in this study have clear cell renal cell carcinoma. Their cancers have metastasized (spread) or are inoperable (cannot be taken out with surgery).
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1 Study of LY4052031 in People With Urothelial Cancer and Other Solid Tumors
Researchers want to find the best dose of LY4052031 to treat people with advanced solid tumors. The people in this study have metastatic solid tumors that came back or keep growing after treatment. In addition, their tumors make a protein called Nectin-4, which plays a role in cancer growth.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1 Study of XmAb819 in People with Kidney Cancer
In this study, researchers want to find the best dose of XmAb819 to treat kidney cancer. The people in this study have clear cell renal cell cancer that keeps growing or came back after standard treatments.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1-2 Study of BNT326 Alone or With BNT327 in People With Advanced Solid Tumors
BNT326 is a type of drug called an antibody-drug conjugate (ADC). ADCs are made of a monoclonal antibody linked to a drug. The antibody binds to a protein on cancer cells called HER3, which plays a role in cancer cell growth. It then releases the anti-cancer drug to kill the cancer cell. By destroying these cells, BNT326 may help slow or stop the growth of your cancer. It is given intravenously (by vein).
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1-2 Study of Nadofaragene Firadenovec in People With Low-Grade Upper Tract Urothelial Cancer
Nadofaragene firadenovec is a gene therapy that delivers a copy of a protein called IFNa2b to your kidney. This may help your immune system find and destroy cancer cells. By killing the cancer cells, nadofaragene firadenovec may cause your cancer to stop growing and spreading.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1-2 Study of ODM-212 in People With Advanced Solid Tumors
Researchers want to find the best dose of ODM-212 to treat advanced solid tumors. The people in this study have solid tumors that have spread and cannot be cured with standard therapies. Examples include:
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1/2 Study of Combination Drug Treatments for People With Urothelial Carcinoma
Researchers want to find the best doses of different drugs to use together in people with advanced urothelial cancer. The people in this study have urothelial cancer that metastasized (spread) and has not yet been treated.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1a Study of CUSP06 in People With Ovarian or Endometrial Cancer
Researchers are finding the best dose of CUSP06 to use in people with advanced ovarian or endometrial cancer. The people in this study have cancer that came back or keeps growing after treatment.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1b Study of HC-7366 and Belzutifan in People With Advanced Kidney Cancer
Researchers want to find the best dose of HC-7366 to use alone and with belzutifan in people with kidney cancer. The people in this study have advanced renal cell carcinoma (kidney cancer) that keeps growing after prior treatments. The cancer either cannot be removed (is inoperable) or has metastasized (spread). 
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1b/2 Study of Abemaciclib and Cabozantinib in People With Kidney Cancer
Researchers want to find the best doses of abemaciclib and cabozantinib to use in people with advanced kidney cancer. The people in this study have clear cell renal cell carcinoma that metastasized (spread); they previously received other kidney cancer therapies. In addition, their cancer keeps growing even after 2 or 3 prior treatments, including checkpoint inhibitor immunotherapy.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau